

CITATION REPORT

List of articles citing

**Chromosomal aberrations and their prognostic value
in a series of 174 untreated patients with
Waldenström's macroglobulinemia**

DOI: 10.3324/haematol.2012.070458
Haematologica, 2013, 98, 649-54.

Source: <https://exaly.com/paper-pdf/56129354/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
108	Waldenström macroglobulinaemia: the key questions. 2013 , 162, 295-303		6
107	Genetic factors and pathogenesis of Waldenström's macroglobulinemia. 2013 , 15, 450-6		10
106	Genomic studies have identified multiple mechanisms of genetic changes in Waldenström macroglobulinemia. 2013 , 13, 202-4		8
105	Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management. 2013 , 88, 703-11		44
104	Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia. 2013 , 88, 948-54		37
103	How to manage Waldenstrom's macroglobulinemia. 2013 , 27, 762-72		33
102	Candidate genes of Waldenström's macroglobulinemia: current evidence and research. 2013 , 6, 33-42		4
101	Macroglobulinémie de Waldenström : de Jan Gosta à MYD88. 2014 , 20, 23-25		
100	The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. 2014 , 123, 1637-46		308
99	Waldenström macroglobulinemia: from biology to treatment. 2014 , 7, 157-68		14
98	Guidelines on the diagnosis and management of Waldenström macroglobulinaemia. 2014 , 165, 316-33		46
97	Acquired initiating mutations in early hematopoietic cells of CLL patients. 2014 , 4, 1088-101		172
96	Waldenström macroglobulinemia at 70. 2014 , 3, 253-266		
95	The cellular origin and malignant transformation of Waldenström macroglobulinemia. 2015 , 125, 2370-80		51
94	Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management. 2015 , 90, 346-54		33
93	Waldenström macroglobulinemia: What a hematologist needs to know. 2015 , 29, 301-19		29
92	Waldenström macroglobulinemia: biology, genetics, and therapy. 2016 , 6, 49-58		3

91	Cytogenetics in the management of lymphomas and lymphoproliferative disorders in adults and children: an update by the Groupe francophone de cytogénétique hématoLOGIQUE (GFCH). 2016 , 74, 568-587	2
90	Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets. 2016 , 57, 1991-2013	17
89	Plasma Cell Dyscrasias. 2016 ,	1
88	Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment. 2016 , 169, 321-361	3
87	Origin of Waldenstrom's macroglobulinaemia. 2016 , 29, 136-147	9
86	Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. 2016 , 175, 77-86	41
85	Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection. 2016 , 17, 16	10
84	HIV Infection and Myelodysplastic Syndrome/Acute Myeloid Leukemia. 2016 , 133-144	3
83	HIV-associated Hematological Malignancies. 2016 ,	4
82	B-cell Non-Hodgkin Lymphomas with Plasmacytic Differentiation. 2016 , 9, 11-28	9
81	Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia. 2016 , 22, 1480-8	68
80	Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management. 2017 , 92, 209-217	37
79	p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell. 2017 , 31, 251-259	34
78	Cytogenetic analysis of hematologic malignant diseases. 2017 , 499-575	1
77	Advances in the role of cytogenetic analysis in the molecular diagnosis of B-cell lymphomas. 2017 , 17, 623-632	2
76	Role of plasma cells in Waldenström macroglobulinaemia. 2017 , 49, 337-345	8
75	IgM myeloma: A multicenter retrospective study of 134 patients. 2017 , 92, 746-751	21
74	Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia. 2017 , 23, 6325-6335	37

73	Waldenström Macroglobulinemia. 2017 ,	
72	Waldenström Macroglobulinaemia: Pathological Features and Diagnostic Assessment. 2017 , 3-19	
71	Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy Chains. 2017 , 239-261	
70	Cytogenetics in Waldenström Macroglobulinemia (WM). 2017 , 49-51	
69	Genetic and Signaling Abnormalities in Waldenstrom Macroglobulinemia. 2017 , 53-65	1
68	Hematopoietic Cell Transplants for Hodgkin Lymphoma. 361-371	
67	Hematopoietic Cell Transplants for Waldenström Macroglobulinemia. 384-391	
66	Toward personalized treatment in Waldenström macroglobulinemia. 2017 , 2017, 365-370	5
65	MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer. 2017 , 10, 133	153
64	Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia. 2017 , 35, 994-1001	47
63	How we manage patients with Waldenström macroglobulinaemia. 2018 , 181, 737-751	5
62	Waldenström Macroglobulinemia. 2018 , 191-220	1
61	Waldenstrom's Macroglobulinemia: An Update. 2018 , 10, e2018004	15
60	Gene Expression Profile Signature of Aggressive Waldenström Macroglobulinemia with Chromosome 6q Deletion. 2018 , 2018, 6728128	4
59	Defining Lymphoplasmacytic Lymphoma: Does MYD88L265P Define a Pathologically Distinct Entity Among Patients With an IgM Paraprotein and Bone Marrow-Based Low-Grade B-Cell Lymphomas With Plasmacytic Differentiation?. 2018 , 150, 168-176	4
58	Cytogenetics of Lymphomas. 2018 , 853-902	
57	Initial Evaluation of the Patient with Waldenström Macroglobulinemia. 2018 , 32, 811-820	6
56	Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond. 2018 , 32, 753-763	4

55	Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma. 2018 , 1419-1431.e5	
54	Waldenström Macroglobulinemia. 2018 , 617-638	
53	Genetics in Lymphomagenesis. 2018 , 723-753	
52	[Waldenström macroglobulinaemia]. 2019 , 48, 832-841	0
51	WITHDRAWN: Updates in Prognostication and Treatment of Waldenström Macroglobulinemia. 2019 ,	1
50	How I treat Waldenström macroglobulinemia. 2019 , 134, 2022-2035	23
49	Updates in prognostication and treatment of Waldenström's macroglobulinemia. 2019 , 12, 179-188	4
48	Laboratory Diagnosis of Chronic Lymphocytic Leukaemia. 2019 , 21-35	2
47	MYD88L265P mutated IgA lymphoplasmacytic lymphoma. 2019 , 75, 608-612	
46	Importance of sequential analysis of TP53 variation in patients with Waldenström Macroglobulinaemia. 2019 , 186, e73-e76	2
45	A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation. 2019 , 9, 796-811	11
44	Chronic Lymphocytic Leukemia. 2019 ,	
43	How Recent Advances in Biology of Waldenström's Macroglobulinemia May Affect Therapy Strategy. 2019 , 21, 27	3
42	TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia. 2019 , 184, 242-245	14
41	Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management. 2019 , 94, 266-276	43
40	Genomic Medicine. 2020 ,	2
39	Recommendations for cytogenomic analysis of hematologic malignancies: comments from the Francophone Group of Hematological Cytogenetics (GFCH). 2020 , 34, 1711-1713	2
38	Lymphoplasmacytic lymphoma and Waldenström macroglobulinaemia: clinicopathological features and differential diagnosis. 2020 , 52, 6-14	6

37	A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. 2020 , 52, 167-178	6
36	Emerging drugs for the treatment of Waldenström macroglobulinemia. 2020 , 25, 433-444	1
35	Identification of 2 DNA methylation subtypes of Waldenström macroglobulinemia with plasma and memory B-cell features. 2020 , 136, 585-595	5
34	Waldenstrom's macroglobulinemia in the era of immunotherapy. 2020 , 61, 1292-1304	1
33	6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival. 2021 , 192, 843-852	7
32	CXCR4 in Waldenström's Macroglobulinemia: chances and challenges. 2021 , 35, 333-345	15
31	Waldenstrom's Macroglobulinemia. 2021 , 143-161	1
30	Molecular Genetics in Indolent Lymphomas. 2021 , 5-20	
29	Flow cytometry detection of CD138 expression continuum between monotypic B and plasma cells is associated with both high IgM peak levels and MYD88 mutation and contributes to diagnosis of Waldenström macroglobulinemia. 2021 ,	1
28	A case report of lymphoplasmacytic lymphoma with paraprotein IgA and IgM. 2021 , 2, e0045	0
27	Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia. 2021 , 23, 361-374	4
26	Managing complications secondary to Waldenström's macroglobulinemia. 2021 , 14, 621-632	
25	Waldenström's Macroglobulinemia: An Exploration into the Pathology and Diagnosis of a Complex B-Cell Malignancy. 2021 , 12, 795-807	1
24	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. 2021 , 195, 210-216	5
23	Molecular Pathology of Mature Lymphoid Malignancies. 2021 , 14, 529-547	
22	Cytogenetic and molecular abnormalities in Waldenström's macroglobulinemia patients: Correlations and prognostic impact. 2021 , 96, 1569-1579	5
21	Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. 2021 , 96, 258-269	12
20	Del17p does not always significantly influence the survival of B-cell chronic lymphoproliferative disorders. 2018 , 9, 3353-3364	3

19	Precision diagnostics in lymphomas - Recent developments and future directions. 2021,	0
18	Waldenström Macroglobulinemia. 2014, 303-329	
17	Lymphomas. 2020, 253-315	
16	PRDM1 expression levels in marginal zone lymphoma and lymphoplasmacytic lymphoma. 2017, 10, 8610-8618	
15	Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions.. 2021,	1
14	Plamotamab (XmAb13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia. 2021, 1-5	1
13	Current approach to Waldenström Macroglobulinemia.. 2022, 31, 100527	1
12	CD5-Negative, CD10-Negative Low-Grade B-Cell Lymphoproliferative Disorders of the Spleen.. 2021, 28, 5124-5147	0
11	Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance.. 2022, 12,	0
10	The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH).. 2022,	1
9	Inflammation in Waldenström macroglobulinemia is associated with 6q deletion and need for treatment initiation. <i>Haematologica,</i>	6.6 0
8	Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study. 2022,	1
7	Plasma cells arise from differentiation of clonal lymphocytes and secrete IgM in Waldenström macroglobulinemia. 2022, 25, 104856	
6	Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies. 2022 , 23, 11145	0
5	Methodological and conceptual challenges to the flow cytometric classification of leukemic lymphoproliferative disorders. 1-18	0
4	Maladie de Waldenström : actualité et perspectives en 2022. 2022,	0
3	The epidemiology of Waldenström macroglobulinemia. 2023,	0
2	Report of Consensus Panel 3 From the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia. 2023,	0

- 1 Cytogenetic aberrations of lymphoplasmacytic lymphoma/Waldenstro m's macroglobulinemia in Chinese patients. Publish Ahead of Print, o